Glythera and IONTAS enter into license agreement for the development of multiple antibodies for next-generation Antibody Drug Conjugates

  •          IONTAS will provide Glythera with antibodies from its fully human antibody libraries
  •          Glythera will use these antibodies, in combination with its novel toxin portfolio, to develop next generation ADCs with improved efficacy and safety, to target difficult-to-treat tumours

 

Cambridge and Newcastle, UK, 20th September, 2017: Glythera Limited (‘Glythera’), the next generation Antibody Drug Conjugate (‘ADC’) development Company, and IONTAS Limited (IONTAS), a leader in services and platform technologies associated with the discovery and optimisation of fully human antibody drugs, today announced a collaboration for the development of ADCs for difficult-to-treat cancers. As part of the agreement, IONTAS will generate novel, fully human antibodies against specified targets for proof-of-concept studies. Glythera will have an option for exclusive, worldwide rights to resulting antibodies for the development of ADCs alongside its proprietary conjugation platform, PermaLink® and its in-house portfolio of novel toxins.

The two companies will select and optimise multiple undisclosed antibodies for ADC development with Glythera exercising its option right to exclusively develop and commercialise the resulting antibodies in ADC formats. Glythera will continue to evaluate numerous ultra-potent ADC-relevant toxin classes, including novel and known mechanisms, with an intention to nominate its first clinical ADC candidate by 2019.

For more information please see the full press release on Iontas's website.

More within